NASDAQ:JANX

Janux Therapeutics Q1 2026 Earnings Results & Report

Janux Therapeutics logo
$10.31 -0.40 (-3.73%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.09 (+0.83%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Janux Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.39 versus the -$0.5202 consensus estimate, while revenue of $3.73 million fell short of the $4.36 million estimate by $624.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Janux Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.5202
Beat/Miss
Beat by +$0.1302
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Janux Therapeutics Revenue Results

Actual Revenue
$3.73 million
Expected Revenue
$4.36 million
Beat/Miss
Missed by -$624.00 thousand
YoY Revenue Growth
N/A

Janux Therapeutics Q1 2026 Earnings FAQ

Janux Therapeutics (NASDAQ:JANX) reported earnings of -$0.39 per share for Q1 2026, beating the consensus estimate of -$0.5202. The report was announced on Thursday, May 7, 2026.

Janux Therapeutics reported revenue of $3.73 million for Q1 2026, against a consensus estimate of $4.36 million.

Janux Therapeutics Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors.

Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.

Based in San Diego, California, Janux was founded in 2017. The company is led by co-founder David Campbell, Ph.D., who serves as president and chief executive officer.

View Janux Therapeutics Profile